Future perspectives in pulmonary arterial hypertension

European Respiratory Review

Volumn 25, Issue 142, 2016, Pages 381-389

  Simonneau, Gérald ^a,b,c   Hoeper, Marius M ^d   McLaughlin, Vallerie ^e   Rubin, Lewis ^f   Galiè, Nazzareno ^g  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; BESTATIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FERRIC CARBOXYMALTOSE; FERROUS SULFATE; IMATINIB; NILOTINIB; PLACEBO; RITUXIMAB; SELONSERTIB; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TOCILIZUMAB; ANTIHYPERTENSIVE AGENT;

CHRONIC MYELOID LEUKEMIA; CONNECTIVE TISSUE DISEASE; DENERVATION; DRUG WITHDRAWAL; GERMLINE MUTATION; HUMAN; IRON DEFICIENCY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRESSORECEPTOR REFLEX; PULMONARY ARTERIAL DENERVATION; PULMONARY HYPERTENSION; REVIEW; SIX MINUTE WALK TEST; STUDY DESIGN; SUBDURAL HEMATOMA; SYMPATHETIC TONE; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT; VASCULAR REMODELING; ARTERIAL PRESSURE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PULMONARY ARTERY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; TREATMENT OUTCOME;

EID: 85000885487     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0084-2016     Document Type: Review

References (79)

1. Humbert M, Lau EM, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189-2208.
2. Galiè N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-844.
3. Pulido T, Adzerikho I, Channick R, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.
4. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522-2533.
5. Humbert M, Simonneau G, Rubin LJ. A decade of achievement in pulmonary hypertension. Eur Respir Rev 2011; 20: 215-217.
6. Sitbon O, Gaine S. Beyond a single pathway - combination therapy in pulmonary arterial hypertension. Eur Respir Rev 2016; 25: 408-417.
7. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010; 87: 356-361.
8. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011; 10: 87.
9. Lythgoe MP, Rhodes CJ, Ghataorhe P, et al. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacol Ther 2016; 164: 195-203.
10. Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: 311-321.
11. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
12. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005; 26: 1110-1118.
13. Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115: 165-175.
14. Cracowski JL, Chabot F, Labarere J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J 2014; 43: 915-917.
15. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 2011; 75: 2668-2674.
16. Kommireddy S, Bhyravavajhala S, Kurimeti K, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford) 2015; 54: 1673-1679.
17. NCT02664558. A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY). 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
18. NCT02736149. Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY2). 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
19. NCT01086540.Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
20. NCT02676947. A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension (TRANSFORM-UK). 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
21. Oudiz R, Meyer C, Chin M, et al. Initial data report from "LARIAT": a phase 2 study of bardoxolone methyl in PAH patients on stable background therapy. Chest 2015; 148.
22. NCT02657356.Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST. 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
23. NCT02234141. GS-4997 in Adults With Pulmonary Arterial Hypertension (ARROW). 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
24. NCT01647945. FK506 (Tacrolimus) in Pulmonary Arterial Hypertension (TransformPAH). 2016. https:// clinicaltrials.gov 2016. Date last accessed: October 21, 2016.
25. NCT01447628. IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients. 2016. https://clinicaltrials.gov 2016. Date last accessed: October 21, 2016.
26. NCT01847352. Iron Status and Hypoxic Pulmonary Vascular Responses. 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
27. Frise MC, Cheng HY, Nickol AH, et al. Clinical iron deficiency disturbs normal human responses to hypoxia. J Clin Invest 2016; 126: 2139-2150.
28. NCT01446848. Oral Iron Supplementation in Pulmonary Hypertension. 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
29. Chen SL, Zhang H, Xie DJ, et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. Circ Cardiovasc Interv 2015; 8: e002837.
30. NCT02525926. Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension (DENERV’AP). 2016. https://clinicaltrials.gov Date last accessed: October 21, 2016.
31. Tian W, Jiang X, Sung YK, et al. Leukotrienes in pulmonary arterial hypertension. Immunol Res 2014; 58: 387-393.
32. Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation 2014; 129: 1332-1340.
33. Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013; 144: 1346-1356.
34. Wilkins MR. Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev 2012; 21: 19-26.
35. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744.
36. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-745.
37. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-1678.
38. Xiong J. BMPR2 spruces up the endothelium in pulmonary hypertension. Protein Cell 2015; 6: 703-708.
39. Spiekerkoetter E, Tian X, Cai J, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013; 123: 3600-3613.
40. van Empel VP, Lee J, Williams TJ, et al. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ 2014; 23: 287-292.
41. Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J 2011; 38: 1453-1460.
42. Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011; 37: 1386-1391.
43. Soon E, Treacy CM, Toshner MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011; 66: 326-332.
44. Krasuski RA, Hart SA, Smith B, et al. Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol 2011; 150: 291-295.
45. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872-1880.
46. Brownlie Tt, Utermohlen V, Hinton PS, et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004; 79: 437-443.
47. Ruiter G, Manders E, Happe CM, et al. Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. Pulm Circ 2015; 5: 466-472.
48. Viethen T, Gerhardt F, Dumitrescu D, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol 2014; 175: 233-239.
49. Robinson JC, Graham BB, Rouault TC, et al. The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol 2014; 51: 721-729.
50. Rothman AM, Arnold ND, Chang W, et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. Circ Cardiovasc Interv 2015; 8: e002569.
51. Juratsch CE, Jengo JA, Castagna J, et al. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest 1980; 77: 525-530.
52. Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013; 62: 1092-1100.
53. Zhang H, Zhang J, Xie DJ, et al. Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease. Pulm Circ 2016; 6: 240-243.
54. Galiè N, Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J Am Coll Cardiol 2013; 62: 1101-1102.
55. Hoeper MM, Galie N. Letter by Hoeper and Galie regarding article, "Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes:phase II results from the pulmonary artery denervation-1 study". Circ Cardiovasc Interv 2016; 9: e003422.
56. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
57. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
58. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
59. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
60. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142: 1383-1390.
61. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144: 952-958.
62. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-413.
63. Mullard A. Reliability of ʼnew drug target’ claims called into question. Nat Rev Drug Discov 2011; 10: 643-644.
64. Colvin KL, Yeager ME. Animal models of pulmonary hypertension: matching disease mechanisms to etiology of the human disease. J Pulm Respir Med 2014; 4: 198.
65. Chandrasekera PC, Pippin JJ. The human subject: an integrative animal model for 21st century heart failure research. Am J Transl Res 2015; 7: 1636-1647.
66. Ross DJ, Hough G, Hama S, et al. Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. Pulm Circ 2015; 5: 640-648.
67. Chelladurai P, Seeger W, Pullamsetti SS. Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. Eur Respir Rev 2016; 25: 135-140.
68. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 2015; 14: 248-260.
69. Gomberg-Maitland M, Bull TM, Saggar R. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol 2013;62: D82-D91.
70. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-291.
71. Hu J, Xu Q, McTiernan C, et al. Novel targets of drug treatment for pulmonary hypertension. Am J Cardiovasc Drugs 2015; 15: 225-234.
72. Dhalla IA, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case-control study. Chest 2012; 141: 348-353.
73. Sadoughi A, Roberts KE, Preston IR, et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest 2013; 144: 531-541.
74. Maurer B, Reich N, Juengel A, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71: 1382-1387.
75. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension:results of the randomized IMPRES study. Circulation 2013; 127: 1128-1138.
76. Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 2015; 34: 1366-1375.
77. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
78. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694.
79. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54: S97-S107.